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Abstract
This study explores the effect of a herpes-simplex viral 
(HSV) vector expressing glutamic acid decarboxylase 67 
(GAD67) in the rat hippocampus.  GAD67 gene transfer 
increases GABA release in transfected neurons by 3 days and 
its effect diminishes over 3 weeks.  Transgene expression was 
associated with a decrease in voltage-gated sodium channel 
α-subunits 1.2 (NaV1.2) and 1.6 (NaV1.6) in the hippocam-
pus.  Changes in VGSC levels, along with enhanced GABA 
neurotransmission, are likely responsible for the prevention of 
status epilepticus in rats expressing the GAD67 transgene us-
ing a pilocarpine-based model of epilepsy. Thus, gene transfer 
of GAD67 under a latency promoter for prolonged expres-
sion may have therapeutic value for patients with intractable 
epilepsy.
Introduction
Epilepsy is a serious neurological condition characterized 
by recurrent, unprovoked seizures.8  An epileptic seizure is a 
transient occurrence of signs and/or symptoms due to abnor-
mal excessive or synchronous neuronal activity in the brain.32  
It is among the most common neurological conditions78, af-
fecting approximately 5 out of every 1000 people in devel-
oped countries96, and it is reported that up to 5% of people 
will experience seizures at some point in their life.6  Decades 
of epilepsy research have identified genetic and acquired 
abnormalities of synaptic and neuronal network instability, 
and over forty subtypes of epilepsy are recognized today.24,27  
Thus, epilepsy is not a single disease but a symptom of brain 
dysfunction: a final common pathway of many different cere-
bral insults.  
Epilepsies may be classified based on etiology as either 
primary (idiopathic) or secondary (symptomatic).  Primary 
epilepsies are those that are not caused by another known 
disorder or syndrome and their etiology is presumed to be 
genetic.  Secondary epilepsies, on the other hand, are the re-
sult of an insult to the patient’s brain, such as a tumor, stroke, 
infection, or trauma.42  Types of epilepsy are further divided 
into partial or generalized based on the clinical presentation; 
partial seizures remain confined to a particular brain region 
while generalized seizures occur bilaterally and throughout 
the forebrain.27
Despite the variety of subtypes, all epileptic seizures can 
be unified as abnormalities in the ongoing electrical activity of 
the brain, and most, if not all, epileptic events arise from some 
type of imbalance between excitatory and inhibitory activity 
within the neuronal circuitry.71  The interconnectivity of neu-
rons makes them particularly susceptible to seizures through 
“runaway” excitation.  Here, activated neurons stimulate 
neighboring neurons in a feed-forward loop, and the result is 
the initiation of synchronous electrical events that are charac-
teristic of seizures.
In the case of partial epilepsy, the region of the brain that 
is responsible for initiating the excitatory activity is often 
identifiable by the sensations, known as auras, perceived at the 
onset of a seizure.  Electroencephalography (EEG) aids in the 
localization of focal epileptogenic abnormalities by detect-
ing aberrant electrical firing through electrodes placed on 
the scalp, and today, functional magnetic resonance imaging 
(fMRI) and positron emission tomography (PET) are often uti-
lized for the accurate localization of abnormal brain activity.24  
These tools provide physicians with the insight necessary for 
diagnosis and treatment of a particular type of epilepsy.
After diagnosis, the first line of treatment utilized in epi-
leptic patients is pharmacotherapy.  A range of anti-epileptic 
drugs (AEDs) are currently in use, but no single drug has 
proven to be universally effective, and combinations of AEDs 
are often used in an attempt to control seizures.  Most AEDs 
have similar mechanisms of action, either blocking voltage-
gated sodium channels (carbamazepine, phenytoin, and lam-
otrigine) or enhancing inhibitory neurotransmission (barbitu-
rates, vigabatrin, and tiagabine).  Understanding the effects of 
these drugs requires knowledge of the neuronal voltage-gated 
sodium channels (VGSCs) and their role in generating and 
propagating action potentials, as well as a familiarity with 
GABA synaptic transmission; these topics will be briefly 
reviewed below.
VGSCs consist of three protein subunits: a pore-forming 
α-subunit and two auxiliary β-subunits, β1 and β2.76  There are 
nine distinct mammalian α-subunits, and specific α-subunits 
are expressed differentially throughout the central and periph-
eral nervous system.  The embryonic hippocampus predomi-
nantly expresses α-subunit 1.3 (NaV1.3), while the adult 
hippocampus expresses α-subunits 1.1, 1.2. and 1.6 (NaV1.1, 
NaV1.2, and NaV1.6, respectively).5,29,36  
These proteins are described as voltage-gated because 
their sodium ion (Na+) pore opens and closes in response to 
changes in cellular membrane voltage.  Gating allows for 
rapid changes in electrical activity to be transferred down 
the axon, and it is essential for the propagation of the action 
potential.  At rest, VGSCs are closed and do not allow Na+ to 
flow through their pores.  However, they have threshold volt-
ages that cause them to open and allow for Na+ flow through 
their pore region.  Once this threshold is reached and the pore 
opens, the Na+ that is accumulated on the outside of the cell 
UMURF       17            Issue 6
Research Article
is allowed to flow into the cell, and the cell becomes depolar-
ized.  This depolarization of the membrane allows more VG-
SCs along the axon to reach their threshold voltage and open 
their pores, allowing the electrical signal to proceed down the 
axon.  
By a similar voltage-gated mechanism, the VGSC pore 
closes to ion flow once the cell reaches a specific membrane 
voltage, and this is known as inactivation.  The closing of the 
pore allows the cell to re-establish the baseline ion gradi-
ent and to prepare for the firing of another action potential.  
Thus, the timing of gating events and the membrane voltages 
at which they occur determine the properties of a particular 
neuron and are important to consider when analyzing the 
excitatory/inhibitory events associated with different types of 
neurons.
Carbamazepine, phenytoin, and lamotrigine are AEDs 
that alter VGSC gating events in order to decrease neuronal 
excitability.  These drugs bind to sodium channels that have 
been inactivated and stabilize the inactivate conformation so 
that the VGSCs remain closed to ion flow.  This has the effect 
of inhibiting action potentials in these neurons.  Based on 
probability, neurons that fire rapid action potentials are more 
likely to be bound and constitutively inhibited, while neurons 
that fire action potentials intermittently are less likely to be 
inhibited.  Therefore, in theory, the proper dose of these AEDs 
should inhibit the aberrant firing of seizure foci while leaving 
the firing associated with normal processes relatively unaf-
fected.80
A second class of drugs that is capable of controlling 
seizures is effective at the level of the synapse.  In the 
prototypical neuron, depolarizing events in the cell body 
trigger the action potential to be propagated down the axon 
and neurotransmitters to be released from the axon terminals 
into the synaptic cleft.  Here the neurotransmitters can bind 
to receptors and trigger changes in the molecular or electri-
cal environment of the neighboring cells.  Barbiturates and 
benzodiazepines are known to be effective at the level of the 
synapse and were some of the first drugs utilized for epilepsy 
treatment. The efficacy of barbiturates and benzodiazepines 
lies partly within their ability to mimic the principal inhibitory 
neurotransmitter in the brain, γ-amino butyric acid (GABA).  
GABA is produced in nerve terminals from the brain’s 
principal excitatory neurotransmitter, glutamate, and is 
released into the synaptic cleft by both vesicular and non-
vesicular mechanisms.119  Once present in the synapse, GABA 
can bind to receptors and inhibit the firing of action potentials 
in neurons.  This is achieved by evoking hyperpolarizing cur-
rents in cells.  Hyperpolarizing currents shift the membrane 
potential away from the threshold required to fire an action 
potential, and thereby inhibit neuronal firing.  GABAA recep-
tors achieve this by allowing chloride ions (Cl-) to flow into 
the cell through an ion pore, while GABAB receptors achieve 
this by intracellular signaling cascades that open potassium 
channels and allow K+ to flow out of the cell. 
In recent years, other AEDs have been developed around 
mechanisms of enhancing GABA-mediated neuronal inhibi-
tion.  Vigabatrin and tiagabine, for example, are drugs that 
serve to increase the brain’s endogenous levels of GABA.  
Vigabatrin accomplishes this by inhibiting GABA transami-
nase39, the enzyme that degrades GABA in the nerve termi-
nals.  Tiagabine, on the other hand, increases GABAergic 
transmission by inhibiting the plasma membrane’s GABA 
transporter (GAT).38  GAT typically serves in the reuptake of 
GABA from the synaptic cleft.  Therefore, inhibition of GAT 
serves to increase the concentration of GABA in the synapse, 
facilitating GABA binding to receptors and increasing inhibi-
tory neural transmission.  
Despite the development of new AEDs, approximately 
20-30% of patients with epilepsy remain refractory to drug 
therapy54,100, and surgical resection of the seizure focus must 
be considered for improving seizure control.  This method 
was first explored as a treatment option in the 19th century, 
and the first successful resection was reported in a patient with 
temporal lobe epilepsy (TLE) in 1879.64,24  TLE is an impor-
tant subtype to consider when discussing surgical treatment 
options since it is the most common type of focal epilepsy, 
the most refractory to pharmacotherapy, and the most acces-
sible to surgical therapy.98,24  Unfortunately, despite extensive 
improvements in surgical techniques, not every epileptic 
patient is a good candidate for surgery and not every seizure 
focus is readily localizable.7  Furthermore, nearly all patients 
that undergo surgery still require additional anticonvulsant 
therapy117 and suffer from the cognitive and behavioral side 
effects of AEDs.
If surgery has been rejected, very few treatment options 
remain.  As a result, alternative treatments are being explored 
using animal-based models of epilepsy, and a variety of 
techniques have been established that can closely mimic TLE 
in humans.  Most commonly, electrical stimulation, electrical 
kindling, and excitotoxin (kainic acid or pilocarpine) adminis-
tration are used for this purpose.  Each of these techniques has 
been proven to mimic the pathophysiologies associated with 
human TLE, including hippocampal sclerosis and electro-
physiological alterations.83,109,110  In our studies, the pilocarpine 
model of seizures was used to induce status epilepticus (S.E.) 
and to explore the possibility of using gene transfer as a novel 
therapeutic approach to epilepsy.
The following studies were designed to explore the efficacy 
of a non-replicating herpes-simplex virus (HSV)-based vector 
in mediating the gene transfer of glutamic acid decarboxy-
lase 67 (GAD67) for the treatment of epilepsy.  GAD67 is an 
enzyme that synthesizes GABA from glutamate.  Neurochemi-
cal studies suggest that a decrease in γ-aminobutyric acid 
(GABAergic) inhibition, particularly in the dentate gyrus of 
the hippocampus, contributes to epilepsy53, and that there is 
potential for treatment through modulation of GABA inhibi-
tory neurotransmission.13   
In our laboratory, the HSV-based vector that encodes 
GAD67 (QHGAD) has been shown to increase GABA 
synthesis and release by transduced neurons.59  The principle 
objective of our study was to test whether focal injection of 
QHGAD in the rat hippocampus would decrease abnormal 
electrical discharges and thus reduce seizure activity in an 
animal model of epilepsy.
Based on current AEDs’ ability for seizure prevention 
(discussed above), we hypothesized that enhanced GABA 
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neurotransmission would reduce seizure activity in a pilo-
carpine-based model of epilepsy.  In addition to its behavioral 
effects, we hypothesized that enhanced GABA release from 
transfected neurons acting on GABAA and/or GABAB recep-
tors in these, or neighboring, neurons would alter neuronal 
expression of VGSCs.  We aimed to explore this effect and to 
determine the mechanisms by which our vector alters these 
channels.
Methods
Experimental Animals.  Female Sprague Dawley adult rats 
(210-230 g) were used.  They were housed with a fixed 12 
hr light/dark cycle and ad libitum access to food and water.  
Housing conditions and experimental procedures were ap-
proved by the University of Michigan Committee on Use and 
Care of Animals.
Vector Construction.  The HSV-based vector had four 
immediate early genes deleted, (ICP4, ICP22, ICP27, and 
ICP47) to block viral gene expression and abort the HSV lytic 
cycle.  The human GAD67 gene is under the control of the hu-
man cytomegalovirus immediate early promoter (HCMV IEp) 
at the UL41 locus in QHGAD.  A green fluorescent protein 
(GFP) reporter gene is also under control of HCMV IEp at the 
UL54 locus.  The control vector, QOZHG, is defective in the 
same four IE genes and contains the GFP reporter gene, but 
the GAD67 gene is substituted with the Escherichia coli lacZ 
reporter gene under control of the herpes promoter infected 
cell polypeptide 0 (ICP0), at the UL41 locus.  Vector stocks 
were produced and stored at −80 °C until thawed for use. The 
QHGAD and QOZHG vectors were purified to a titer of 5 x 
106 pfu/μL.  Vector Constructs are shown in Figure 1.
Stereotactic injections.  Two vectors were used in these ex-
periments: Control vector, QOZHG, and experimental vector, 
QHGAD.  Animals were injected with the appropriate vector 
bilaterally into the dentate gyri (nose bar, 0 mm; lateral, +/-2.8 
mm from Bregma; anterior/posterior, -3.8 mm from Bregma; 
ventral, -3.5 below the dura) using a 10 μL Hamilton syringe.  
3 μL of the vector was injected at a rate of 0.33 μL/min and 
all animals were fully anesthesized throughout surgery (4% 
chlorohydrate, 1 mL/kg, intraperitoneally (i.p.)).  Damage to 
the dentate gyrus was avoided to our best ability, and no be-
havioral differences were seen in these animals post -stereot-
actic injection.  For seizure experiments, control vector and 
QHGAD vector were aliquoted and labeled numerically by 
an outside source.  The numbered vectors were injected, and 
behavioral testing was performed before the identity of the 
vector was known, eliminating researcher bias.  Pilocarpine 
was administered three days post-stereotactic injection.  
Pilocarpine administration.  As Figure 2 illustrates, each 
rat was pre-treated with scopolamine (1 mg/kg, i.p.) before 
pilocarpine administration (400 mg/kg, i.p.).  The animals 
were closely monitored and any seizure behavior was re-
corded for 90 minutes.  At 90 minutes, each animal, regardless 
of seizure severity,  was given a dose of diazepam (5 mg/kg, 
i.p.) regardless of seizure severity.  The animals were then 
given a dose of 4% chlorohydrate (1 mL/kg, i.p.) to ensure full 
anesthesia before sacrificing the animals.  
Behavioral Measurements.  After pilocarpine injection, 
animals were observed for 90 minutes for seizure-specific 
behaviors.  The latency to mouth/facial movements and head 
bobbing, defined as stage 1 and stage 2 seizures, respectively, 
was recorded.87  In strongly affected animals, these behaviors 
were followed by recurrent myoclonic convulsions, rearing, 
falling, and S.E.109  S.E. was defined as persistent seizure 
activity that was uninterrupted by voluntary or coordinated 
movement.  The occurrence of S.E. was recorded in all ani-
mals, and the latency to S.E. was noted when applicable.
Cell Culture.  Hippocampal neurons from Sprague Dawley 
rat pups on post-natal day 1 were obtained, dissociated, and 
plated over poly-lysine coated 24-well plates.  Hippocampal 
neurons were cultured in defined Neurobasal media supple-
mented with B27, Glutamax I, and Albumax II.  After 3 weeks 
in culture, cells were incubated with the appropriate viral 
vector (MOI 3) for 2 hours before the media was removed and 
fresh media was added.  The cells were left to express the vec-
tor for 48 hours, at which point approximately 95% of cells 
expressed the reporter gene, GFP, as observed using fluores-
cent microscopy. 
Figure 2: A schematic representation of the seizure induction protocol.
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Western Blot Analysis. Animals were perfused transcardi-
ally with 100 mL 0.9% NaCl and the brain was collected and 
frozen on dry ice immediately.  The hippocampus was then 
dissected from the surrounding cortex and the tissue was 
homogenized in sample buffer (2% SDS, 1% glycerol, 0.5% 
Tris Buffer) containing phosphatase inhibitors (Sigma, p2850 
& p5726) and a protease inhibitor (Sigma, P8340).  Care 
was taken to avoid the precipitation of SDS.  The homo-
genate was then sonicated and subsequently centrifuged at 
14,000 rpm for 5 min before the supernatant was collected.  
High-speed fractionation studies were performed on noted 
samples, which included a spin at 80,000 rpm for 60 minutes.  
Bio-RAD Dc protein assay was performed to determine all 
protein concentrations and 50 μg aliquots were prepared for 
analysis.  All samples were run on 4-15% or 7.5% tris-HCl 
gels from Bio-RAD.  Primary antibodies were obtained from 
Chemicon, Temecula, CA (GAD67, 1:1000; NaV1.2, 1:200; 
NaV1.6, 1:200; β2, 1:300) and Sigma-Aldrich, St. Louis, MO 
(β-actin, 1:2000)), and species-specific secondary antibodies 
were obtained from Santa Cruz Biotechnology, Santa Cruz, 
CA (1:2000).  All antibodies were diluted in 5% milk solu-
tion prepared in 1x PBS.  Exposure of antibody binding was 
performed with chemiluminescent HRP antibody detection 
reagent from Denville Scientific (E-2500).  Densitometry 
analysis was performed using Quantity One software.  Experi-
ments using cell lysates were also prepared according to the 
methods listed above.
Immunohistochemistry.  Animals were perfused transcardi-
ally with 150 mL 0.9% NaCl and subsequently with 200 mL 
4% paraformaldehyde (PFA) buffered at a pH of 7.4.  The 
brains were then dissected and post-fixed for 24 hours in PFA 
and dehydrated for 48 hours in a 30% sucrose solution.  Forty 
μm thick sections were taken using a sliding microtome, 
and slices were kept in antifreeze solution (sucrose, ethylene 
glycol, phosphate buffer) at -20oC until use.  Antibodies used 
include those listed above, as well as c-fos (1:500, Santa Cruz, 
SC-7202).  Fluorescent, species-specific, secondary antibod-
ies (1:2,000, Alexa Fluor) were used in immunofluorescent 
assays, and DAB stains were performed using reagents from 
Vector Laboratories, Inc.
Immunocytochemistry.  Cells were directly fixed in 10% 
formalin solution, blocked (5% NGS, 1% BSA, 0.01% 1000x 
sodium azide, 0.2% Triton), and probed with the appropri-
ate antibodies diluted in solution (5% NGS, 1% BSA, 0.01% 
1000x sodium azide).  Cells were then probed with fluores-
cent, species-specific, secondary antibodies (1:2000, Alexa 
Fluor)), and cells were mounted using Fluoromount-G (Elec-
tron Microscopy Sciences, 17984-25).  
Imaging.  Confocal microscopy was performed using the 
Zeiss 510 Meta Microscope from the Microscopy and Image 
Analysis Core Facility in the University of Michigan Biomed-
ical Science Research Building. 
Statistical Analysis.  Statistical significance was obtained 
for the seizure animals using a Fisher Exact Test.32  For 
Western blot analysis, one-tailed Student t-tests were applied 
to densitometry ratios when the number of samples per group 
was sufficient.
Results
GFP and GAD67 transgene expression in rat hippocampus 
following HSV-vector delivery
To determine the extent of neuronal infectivity and trans-
gene expression in rat hippocampus after HSV-vector delivery 
to the dentate gyrus, a series of histological and biochemical 
studies were performed.  
Injection of the HSV-vector into the rat hippocampus was 
adjusted to give the maximum amount of expression in the 
dentate gyrus region and to minimize the damage to surround-
ing tissue.  Ultimately, 3 μL of the vector injected at a rate of 
0.33 μL/minute in a region dorsal to the dentate gyral superior 
blade was determined to be ideal; these settings were utilized 
for all subsequent experiments.  
The extent of vector-mediated transgene expression was 
visualized using a green fluorescent protein (GFP) reporter 
gene present in QHGAD and QOZHG vector control (Figure 
3).  Injection of the vector resulted in widespread expression 
in the granule cells of the dentate gyrus (3b), as well as the 
Figure 3: GFP expression in the rat hippocampus upon QHGAD inoculation.  3 days post-injection, GFP is present throughout the hippocampus, and 
the injection did not seem to cause any serious tissue disruption (a).  Granule cells of the dentate gyral superior blade display the strongest expression 
(b), and significant expression is also seen in the CA1-CA3 regions (CA1, c).  The injection site is indicated with an asterisk(*).
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pyramidal cells of the hippocampal CA1-CA3 regions (3c) 3 
days post-injection.  The expression in the dentate gyrus was 
specific to the granule cell layer and did not show notable ex-
pression in the neurons of the dentate hilus.  GFP is observed 
in neuronal cell bodies, as well as neurites, indicating wide-
spread transgene expression intraneuronally.  These results 
were maintained at the 1 week time point, but were largely 
diminished by 2 weeks and were absent by 3 weeks.  
The level of GAD67 transgene expression was measured 
by Western blot of protein homogenates from animals injected 
in the dentate gyrus with QHGAD, control vector (CV), or 
saline.  Results showed that QHGAD treated hippocampi 
expressed very high levels of GAD67 protein at 3 days post-
injection as compared to sham animals and control vector 
injected animals (Figure 4).  The electrophoretic mobility of 
the GAD67 transgene protein appears slightly faster than the 
endogenous band seen in sham animals.  Animals injected 
with saline alone showed the same band as sham animals, 
suggesting that the change in mobility was not due to trauma.  
We are unclear about the exact nature of this slight increase 
in electrophoretic mobility of the GAD67 transgene protein, 
but it is possibly due to differences in glycosylation levels 
or phosphorylation state.  In the high speed pellet fraction of 
these samples (100,000g), a single molecular weight band was 
observed instead of the doublet, indicating a possible mem-
brane associated fraction of GAD67.  Again, protein expres-
sion was robustly increased in the QHGAD sample.
These results showed that the direct delivery of a non-
replicating HSV-vector to a focal brain regions leads to a high 
efficacy of neuronal infection and robust levels of transgene 
expression.  Also, the time course observed was characteristic 
of what we have previously seen using the HCMV promoter.  
Thus, these vectors were determined suitable for further stud-
ies in epilepsy.
Over-expression of the GAD67 transgene provides resistance 
to pilocarpine-induced status epilepticus
Using the behavioral analysis described above (see Meth-
ods), seizure activity characterized by mouth/facial move-
ments, head bobbing, convulsions, and status epilepticus was 
recorded. All animals were observed for 90 minutes following 
the administration of pilocarpine, and latencies to different 
seizure activities were recorded.  Preliminary experiments 
were performed to determine an optimal dose of pilocarpine 
for inducing status epilepticus (S.E.) in vector injected ani-
mals, and it was concluded that a dose of 400 mg/kg, preceded 
by scopolamine (1 mg/kg), was the maximum dose that could 
be administered without risking mortality.  This dose was ca-
pable of producing S.E. in 75% of QOZHG-injected animals, 
which is similar to the percentage reported by others for sham 
animals.53
Three days prior to pilocarpine administration, all animals 
were injected with 3 μL of the appropriate vector containing 
5x106 pfu/μL.  These animals were injected bilaterally in the 
dentate gyri, as described previously in studies of GAD67 
transgene expression.
Treatment with QHGAD was capable of reducing the per-
centage of animals to reach S.E. in this model of seizures, and 
the results were statistically significant (p < 0.05) (Figure 5).  
Figure 4 (Top): GAD67 transgene protein expression from rat 
hippocampus.  A shows the Western blot analysis of hippocam-
pal protein three days post-injection and the strong expres-
sion of GAD67 with the QHGAD vector.  CV is control vector, 
S is the supernatant fraction and P is the pellet fraction of 
homogenates.  B illustrates that the lower band detected with 
the GAD67 antibody is not due to trauma (saline injection), 
but is present with injection of control vector.  C depicts the 
regions of the hippocampi that were isolated from rat brain for 
Western blot analysis. 
Figure 5 (Left): QHGAD inoculated animals are resistant 
to status epilepticus (S.E.) upon pilocarpine administration.  
Six out of  eight control vector inoculated animals reached 
S.E. in this seizure assay while only one out of eight QHGAD 
inoculated animals reached S.E. when given the same dose of 
pilocarpine.  Statistical analysis was performed using a Fisher 
Exact Test and the difference observed is significant, p < 0.05.
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Six out of eight  animals injected with control vector experi-
enced S.E. while only one out of eight animals injected with 
QHGAD experienced S.E.  The latencies to onset of stage 1/2 
seizure activity and S.E. were highly variable between groups 
and results were not statistically significant.
In addition, we examined brain sections from these animals 
for c-fos expression with immunocytochemistry.  Analysis of 
c-fos expression in the hippocampus can be correlated with 
seizure activity, as reported by others.21,43,22  Animals that did 
not reach S.E., independent of treatment group, show low bas-
Figure 6: Expression of c-fos in the dentate gyrus (a,b,c) and CA2 regions (d,e,f) after pilocapine administration.  a and d are sections from a QHGAD 
injected brain that did not reach S.E.   b and e are sections from a control vector injected brain that reached S.E.  Strong expression of c-fos is seen 
in the dentate gyrus and CA2 region.  c and f are sections from a QHGAD vector injected animal that reached S.E.  The dentate gyrus of this animal 
resembles the non-S.E. dentate gyrus (a) with low c-fos expression, but the CA2 region of this brain shows expression of c-fos similar to that in the S.E. 
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al levels of c-fos expression in the hippocampus, and QOZHG 
injected animals that reached S.E. showed a strong up-regula-
tion of c-fos in dentate granule cells and CA1-CA3 pyramidal 
cells (Figure 6).  Interestingly, the single animal injected with 
QHGAD that reached S.E. did not show c-fos up-regulation in 
the dentate granule cells but did show some level of c-fos im-
munostaining in the hippocampal CA1-3 regions as compared 
to animals with no seizures, indicating that another pathway 
may have been responsible for initiating S.E.
The results from these experiments showed that prevention 
of clinical seizures may be obtained though HSV-mediated 
GAD67 transgene delivery to the seizure focus.
Long term enhanced synthesis and release of GABA from 
over-expression of GAD67 down-regulates VGSCs in treated 
hippocampus
Changes in VGSC expression and properties have been 
described in different animal models of epilepsy, and it has 
been reported that these changes can play a critical role in 
the development of seizures.1, 23, 51, 61, 116 For this reason, we 
hypothesized that the enhanced release of GABA result-
ing from QHGAD inoculation may affect the levels of the 
voltage-gated sodium channels.  We examined the presence 
of NaV1.1, 1.2, and 1.6, since these are the subunits present 
within the adult hippocampus.  Protein levels were examined 
3 days after vector injection in animals that were not treated 
with pilocarpine. 
We observed a strong decrease in the presence of NaV1.2 
and NaV1.6 in response to QHGAD compared to QOZHG 
and control brains (Figure 7, Figure 8).  We then examined 
the time dependence of this down-regulation and concluded 
that NaV1.2 and NaV1.6 were down-regulated to the great-
est degree when the GAD67 expression was the highest.  
By Western blotting, we show that these α-subunit protein 
levels are greatly diminished at one week but are increasing 
at two and three weeks when GAD67 transgene expression 
is diminishing (Figure 9, Figure 10).  NaV1.1 was unable 
to be examined with this method due to antibody limitations.  
Immunofluorescent staining of α-subunit proteins was also 
attempted, but the resolution of this method was not sufficient 
to display these changes in protein levels.
We examined the levels of β2 protein in the hippocampus 
Figure 7 (Top): NaV1.2 is down regulated in QHGAD injected animals.  
Western blot analysis of hippocampal tissue shows decreased levels of 
NaV1.2 at 3 days post-injection (A).  A ratio of the mean intensity of the 
NaV bands to control (β-actin) is depicted in B.  Bars represent standard 
error of the mean.  Differences between the groups indicated were statis-
tically significant, p<0.05, using a one-tailed Student’s t-test. Figure 8 ( 
Right): NaV1.6 is down regulated in QHGAD injected animals.  Western 
blot analysis of hippocampal tissue shows decreased levels of NaV1.6 at 
3 days post-injection (A).  A ratio of the mean intensity of the NaV bands 
to control (β-actin) is depicted in B.  The blot shown is representative of 
several trials showing NaV1.6 down regulation.
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since the β-subunits of VGSCs are important for the insertion 
and maintenance of α-subunits in the plasma membrane, but 
we did not observe significant change upon administration of 
QHGAD (Figure 11).  These findings suggest that the regula-
tion of the NaV1.2 and 1.6 protein levels by GAD67 transgene 
expression may be independent from the regulation of the 
β2-subunits in these cells.
The occurrence of VGSC α-subunit down-regulation upon 
QHGAD inoculation signifies that QHGAD prevention of S.E. 
may not have been strictly due to enhanced GABA release, 
but may have been partly due to a decrease in the VGSC 
α-subunits that are crucial for action potential propagation.
VGSC α-subunits are localized in hippocampal neurons
In order to examine if the regulation of VGSC α-subunits 
was localized in neurons or glial cells of the hippocampus, 
immunocytochemistry was performed.  NaV1.1, 1.2, and 1.6 
α-subunits were all seemingly localized to neurons, as 
visualized by the co-localization of VGSC proteins with the 
neuronal marker MAP2 (Figure 12).  The co-localization we 
detected was specific to granular layer neurons of the den-
tate gyrus and pyramidal neurons of the CA1-CA3 regions, 
and strong expression of NaV1.1 and 1.2 was observed in 
neuronal plasma membranes.  NaV1.6 was detected more 
uniformly throughout the cell body, but this effect may be due 
antibody quality. 
These findings suggest that the down-regulation in VGSC 
α-subunits observed upon QHGAD injection in the hippocam-
pus is specific to neurons, not glial cells, and therefore may 
have a direct effect on action potential propagation in these 
cells.
Absence of QHGAD regulation of VGSC α-subunits in vitro
Experiments using hippocampal neurons in culture were 
performed in an attempt to further characterize the cellu-
lar mechanisms involved in the down-regulation of VGSC 
α-subunits in response to QHGAD.  
Hippocampal neurons were obtained from neonatal rat 
pups on post-natal day 1 and cultured for 3 weeks.  VGSC 
α-subunits were examined in this cell culture by immunocy-
tochemistry, as they were examined in vivo.  Co-localization 
experiments were performed with antibodies to NaV1.1, 1.2, 
1.6, and the neuronal marker MAP2.  These experiments 
showed dominant VGSC α-subunit expression in neurons, 
rather than astrocytes (Figure 13).  
It should be mentioned that low levels of VGSC staining 
were observed in occasional astrocytes in vitro when double 
labeled with GFAP, but this effect was not uniform, and the 
Figure 9: Response of NaV1.2 to GAD67 transgene expression over a 3-week timecourse.  NaV1.2 protein expression is inversely related to GAD67 
transgene expression over this time period.  B and C illustrate the ratio of the GAD67 band mean intensity or  VGSC band mean intensity to control 
(β-actin), respectively. 
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levels were substantially lower than those detected in neurons.
Upon transfection with QHGAD, cultured hippocampal 
neurons displayed pronounced GFP expression and displayed 
a large increase in GAD67 protein observed with Western 
blotting (Figure 14).  However, in preliminary experiments 
these neurons did not show the regulation of VGSCs observed 
in vivo.  
These experiments lead us to believe that the VGSC 
α-subunit regulation that we observe in vivo is occurring in 
neurons, but the effect is somehow specific to adult hippocam-
pal neurons or is dependent on the intact neuronal circuitry 
present in an in vivo model.  
Discussion
The high prevalence of drug-resistant epilepsy requires 
patients to undergo surgical resection of the seizure focus 
often as a last treatment option.  Unfortunately, not all patients 
are eligible for surgery based on their medical history and/or 
the location of their seizure focus.  The development of other 
treatment options for these patients is necessary, and our stud-
ies suggest that GAD67 gene transfer to the seizure focus may 
provide a therapeutic option for epilepsy management.
Progress in the development of non-replicating viral vec-
tors has greatly advanced their potential use in clinical gene 
therapy, and HSV-based vectors have gained a great deal of at-
tention due to its their many desirable characteristics.  HSV’s 
ability to establish a latent state in the nucleus of non-dividing 
cells, such as neurons, as a non-integrated episomal element 
makes it particularly useful.  This mechanism allows the viral 
genome to remain latent in the host cell without disrupting the 
host genome.74  Furthermore, HSV’s genome can be manipu-
lated to decrease its toxicity and to carry relatively large genes 
for transfer to host cells.31  For these reasons, HSV-based 
vectors have been explored as clinical treatment options, and 
they have been shown to be well tolerated and safe when 
delivered to a variety of tissues, including the brain.40, 68, 79, 85, 89 
The QHGAD vector was previously shown to be effective in 
the transduction of dorsal root ganglion neurons and was able 
to greatly increase the release of GABA from these cells in 
vitro and in vivo.59  In our studies, QHGAD was capable of 
Figure 10: Response of NaV1.6 over a three week timecourse.  The 
NaV1.6 protein level is regulated in a similar manner to NaV1.2.  It is 
decreased at 1 week, but increases in expression in week 2 and 3 (A).  B 
is a ratio of the mean intensity of the VGSC bands to control (β-actin).
Figure 11: VGSC β2-subunit protein does not show any alteration 
between control, control vector, and QHGAD after 3 days of expression, 
as is seen in the NaV1.2 and NaV1.6 levels.  Western blot of the protein 
is shown in A.  B shows a ratio of the mean intensity of the β2 bands to 
control (β-actin) bands.  Bars represent standard error of the mean.  Dif-
ferences are not statistically significant.
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transfecting hippocampal neurons (Figure 3) and expressing 
GAD67 protein in this tissue (Figure 4).  
Endogenous properties of GAD67 make it particularly 
favorable for epilepsy treatment.  The two isoforms, GAD65 
and GAD67, are each encoded by a single, separate gene, and 
they are distinct in their intracellular distributions in neurons.11 
In general, GAD65 is prevalent in axon terminals and syn-
aptic vesicles, whereas GAD67 is located in cell bodies and 
uniformly distributed throughout the neuron.56  The levels of 
GABA synthesized by these enzymes differ since GAD65 is 
bound to its cofactor, pyridoxal 5’-phosphate (PLP), less often 
than GAD67, making GAD67 more constitutively active in 
neurons.3  Thus the transfer of the GAD67 gene rather than the 
GAD65 gene allows for the bypass of this regulation and the 
constitutive production of GABA in transfected neurons.
Sequestering of neurotransmitters in synaptic vesicles 
provides another level of control for neurons.  Shifts in 
membrane potential and subsequent increases in intracellular 
calcium ions are able to control the trafficking of synaptic 
vesicles to the plasma membrane, where they release their 
Figure 12: Tissue sections show the possible co-localization of NaV1.1 (A,B,C), 1.2 (D,E,F), and 1.6 (G,H,I).  A, D, and G are hippocampal neurons 
stained with MAP2, and images B, E, and H are VGSC α-subunits stained with the antibody corresponding to the specific subtype.  C, F, and I are 
overlays of these images displaying co-localization.
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contents into the synaptic cleft.  Typically GABA is released 
at the synapse, binds to GABA receptors, and causes hyperpo-
larization.  Interestingly, it has been reported that a decreased 
quantal release of GABA from synaptic vesicles may con-
tribute to epileptogenic activity in experimental models of 
temporal lobe epilepsy.44  
In addition to synaptic release, the reversal of the GABA 
transporter, GAT-1, has been observed as a non-vesicular 
mechanism of GABA release.  GAT-1 undergoes the coupled 
translocation of Na+, Cl-, and GABA in a ratio of 2:1:163, 
and the transporter can be reversed by increased intracellular 
concentrations of Na+ and GABA (119, 120, 121).  QHGAD 
has been reported to release GABA in this fashion in trans-
fected DRG neurons, and thus it has the potential to release 
GABA constitutively, independent of membrane potential and 
synaptic vesicle activity.59
Animal models of seizures and epilepsy allow for the 
mechanisms, as well as the treatments, of epilepsy to be exten-
sively researched.  In the 1980s, the excitotoxin pilocarpine 
was determined to be valuable for designing new therapeu-
Figure 13: Immunofluorescent staining of hippocampal neurons in vitro shows the strong co-localization of a neuronal marker (MAP2) with NaV1.1 
(a,b,c), 1.2 (d,e,f), and 1.6 (g,h,i).  A, C, and Fare hippocampal neurons stained with MAP2, and images B, E, and H are VGSC α-subunits stained with 
the antibody corresponding to the specific subtype.  C, F, and I are overlays of these images displaying co-localization.
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tic approaches to epilepsy.109  Pilocarpine was observed to 
provoke seizure-characteristic behaviors, and to produce 
long-term effects of epilepsy and seizure related brain dam-
age.83  Today, the pilocarpine model of epilepsy allows us to 
conduct two types of pharmacological studies: acute studies 
concerning our treatment’s efficacy against status epilepticus; 
and chronic studies concerning our treatment’s potential for 
prevention of recurrent seizures.  
To date, we have only completed the first round of studies 
using QHGAD, but the efficacy of the vector is encouraging.  
We showed that QHGAD inoculation in the rat dentate gyrus 
was able to prevent status epilepticus in 87.5% of animals 
injected with pilocarpine, while only 25% with control vector 
inoculation were protected from S.E. upon pilocarpine admin-
istration.  Results from the QOZHG group are consistent with 
other reports from sham animals53, and inter-animal variability 
likely accounts for the percentage of these animals that did not 
reach S.E.58  
It has been previously determined that seizure activity 
results in rapid and transient c-fos up-regulation in dentate 
granule cells and CA1-CA3 cells, reaching maximum levels 
within 30 minutes of seizure termination.20,21,22  We used this 
marker as a confirmation of seizure activity in QOZHG and 
QHGAD injected animals in an attempt to support behavioral 
findings.  We found that the seizures experienced by control 
and QOZHG inoculated animals were consistent with an up-
regulation of c-fos in these regions.  Furthermore, QHGAD 
injected animals that did not exhibit S.E. did not show an up-
regulation of c-fos.  
Interestingly, the single QHGAD inoculated animal that 
reached S.E. did not follow this trend.  This animal did not 
show the strong up-regulation in dentate granule cells, but did 
show some degree of up-regulation in CA1-3 regions (Figure 
6).  We are unable to fully explain this novel finding, but we 
hypothesize that the high expression of GABA in the dentate 
granule cells and their strong inhibition remained intact, and 
status epilepticus was reached through another pathway in the 
brain.  The perforant pathway connecting the entorhinal cortex 
(EC) to the CA1-3 regions is a possible candidate.  The EC is 
believed to be a seizure origin for many patients with TLE38, 
and it has been reported that neurons leaving the EC can 
stimulate the CA1-3 regions without stimulating the dentate 
gyrus26.  Based on in vitro studies showing the contribution 
of the CA regions to seizure initiation and maintenance, we 
believe that this mechanism was the possible pathway for 
generalized seizure induction2.
Many alterations in brain protein composition have been 
observed in animal models of epilepsy as well as human epi-
leptic hippocampus, and compensatory mechanisms of VGSC 
regulation are noted to occur in sodium channels’ α-subunits, 
as well as their β-subunits.23,111,116  We hypothesized that 
the continuous release of GABA from QHGAD transfected 
neurons would alter the electrical environment and result in 
an alteration of VGSCs.  We examined NaV1.1, 1.2, and 1.6 
because of their marked presence in adult hippocampus29, and 
the β2-subunit because of its association with these channels 
and its reported alterations with seizure activity.17,76
Analysis after 3 days of QHGAD expression revealed a 
strong down-regulation of NaV1.2 and 1.6 proteins (Figure 
7, Figure 8); the decrease was statistically significant for 
NaV1.2, and experiments are currently underway to increase 
the sample size and to perform statistical analysis on NaV1.6 
bands.  We also observed that this down-regulation correlated 
with the level of vector-mediated GAD67 expression, as 
shown in the 3 week time course (Figure 9, Figure 10).  
The continuous release of GABA having an effect on 
VGSC α-subunit protein levels is a novel finding that has not 
been reported by other groups.  In order to gain insight to this 
effect, we designed experiments to determine what cell types 
were expressing these VGSCs and what mechanisms were 
responsible for their down-regulation.
Since it has been reported that hippocampal astrocytes, like 
neurons, exhibit VGSC electrophysiological properties10,103,  
we utilized immunofluorescent staining to determine the cel-
lular localization of NaV1.1, 1.2, and 1.6 in rat hippocampus.  
Immunostaining of tissue slices suggests that the proteins 
being detected are neuronal in origin, but due to the limita-
tions of light microscopy, we cannot rule out that a portion of 
the proteins detected are in astrocytes in close association with 
labeled neurons.  These experiments were repeated in vitro, 
and a confirmation of the prevalent neuronal localization was 
observed (Figure 11), with the exception of occasional astro-
cytes staining for low levels of these α-subunits.
The down-regulation of VGSCs is associated with sev-
eral neurological diseases and insults, such as epilepsy and 
ischemia, yet little is known about the mechanisms of down-
regulation.  It has been proposed that neuronal VGSCs may 
be the targets of the ubiquitin-protein ligases of the Nedd4 
family33,95, but we have not ruled out decreased transcrip-
tion of VGSC genes as a mechanism of the down-regulation 
resulting from QHGAD.  Experiments looking at VGSC α 
and β-subunit mRNA levels by reverse transcription-PCR are 
currently underway.
In an attempt to explore the mechanism of VGSC α-subunit 
down-regulation, we utilized the dissociated hippocampal 
neurons from rat neonates and transfected these cells with 
Figure 14: Western blotting detects a strong increase in GAD67 protein 
upon QHGAD infection in vitro, but a decrease in NaV1.2 and/or 1.6 is 
not detected.  NaV1.2 is shown here.  The blot displayed is representative 
of several trials.
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QHGAD.  We aimed to determine if blocking GABAA and/
or GABAB receptors would abolish the observed down-regu-
lation.  However, the down-regulation of α-subunits was not 
observed in this cell culture as it was observed in vivo, despite 
strong GAD67 expression (Figure 14).  We hypothesize that 
this may be due to several factors including the lack of an 
intact neuronal network (as is present in vivo) or the molecular 
differences between neonatal and adult hippocampal neurons.  
It has been reported that early in development, GABA 
serves as an excitatory neurotransmitter in the brain due to the 
decreased expression of the potassium chloride cotransporter, 
KCC2.57,92  We hypothesize that this reversed effect of GABA 
in neonatal cells may be responsible for eliminating the 
mechanism of voltage-gated sodium channel regulation.  
Another possible explanation for this phenomenon lies 
within the relative abundance of NaV1.1, 1.2, 1.3, and 1.6 
in the hippocampus.  Levels of these proteins are reported to 
change between neonatal and adult life, with 1.3 being the 
predominant VGSC α-subunit in neonatal hippocampi.5,29  We 
hypothesize that NaV1.3 levels are high in our hippocampal 
neuron culture and that these proteins, rather than NaV1.2 
and 1.6, may undergo down-regulation after QHGAD infec-
tion.  Experiments to test the levels of NaV1.3 have yet to be 
conducted, but we plan to complete these experiments in the 
near future. 
Also, experiments using an organotypic slice preparation 
of adult rat brains are being planned to determine if an intact 
neuronal network is necessary for the regulation of VGSC 
α-subunits and to eventually explore the electrophysiological 
properties of this type of VGSC regulation.
In addition to exploring VGSC α-subunit regulation, future 
experiments will need to assess the ability of QHGAD to be 
an effective treatment for chronic epilepsy.  It may prove that 
QHGAD does not provide the long-term protection that is 
needed due to the short time span of GAD67 expression, and 
in this case, a vector should be constructed with a longer act-
ing promoter in place of the HCMV promoter.  Studies using 
the HSV-latency promoter LAP2 for long term expression 
have been previously published and show transgene expres-
sion for up to one year.18,91  Chronic studies will allow us to 
determine whether GAD67 transgene expression is capable 
of preventing recurrent seizures over months or years.  The 
results of this type of study will provide better insight to the 
clinical capabilities of gene therapy in the setting of anticon-
vulsant-resistant epilepsy.
It has been extensively observed that the cellular envi-
ronment of the cortex and the hippocampus can give rise to 
seizure activity by a variety of mechanisms.  These include 
alterations in VGSCs23, “burst-generating” cell activity71, 
shifts in EGABA due to K+/Cl- cotransporter regulations86, and 
synchronization of cell firing due to ephaptic interactions47.  
Despite the variation, all of these epileptic mechanisms could 
be conducive to improvement by enhanced GABAergic activ-
ity, and GAD67 gene transfer provides a reasonable method of 
achieving this enhancement.
Thus, the development of novel treatments for epilepsy 
is ongoing, and the results from our experiments, as well as 
other studies in gene therapy, show promise toward manage-
ment of intractable epilepsies.49,72,91,121  As previously shown, 
HSV-vectors can provide a safe and effective means for 
transgene delivery, and hold great potential for the future of 
gene therapy.  The findings presented above are encourag-
ing for the possible use for GAD67 transgene expression as a 
treatment for epilepsy, but many critical experiments remain 
to be pursued.
Acknowledgements
This work was made possible though the extensive support 
of Dr. Marina Mata, Dr. David Fink, and their laboratory staff. 
I would like to personally thank Dr. Xiangmin Peng and Dr. 
Munmun Chattopadhyay for my training in molecular biology 
techniques, Mr. John Timm for my training in stereotactic in-
jections, and Mr. Vikrum Singh-Thakur for purification of the 
vectors.  I would also like to thank Ms. Michelle Kron for my 
training in the pilocarpine model of epilepsy and Dr. Jack Par-
ent for allowing me to work under his protocol.  Most of all, I 
would like to thank Dr. Mata and Dr. Fink for granting me the 
opportunity to complete an honors thesis in their laboratory 
and for providing me with constructive support throughout the 
writing process.
References
  1.   N. Agrawal, A. Alonso, D. S. Ragsdale, Epilepsia 44, 1601 
(2003). 
  M. Avoli, M. D'Antuono, J. Louvel, R. Kohling, G. Biagini, 2.   
R. Pumain, G. D'Arcangelo, V. Tancredi, Prog Nurobiol, 68, 
167-207 (2002).
  D. S. Barth, W. Sutherling, E. J. Jr, J. Beatty, 3.   Science 223, 
293 (1984). 
  G. Battaglioli, H. Liu, D. L. Martin, 4.   J Neurochem 86, 879 
(2003). 
  M. F. Bear, B. W. Connors, M. A. Paradiso, Neuroscience: 5.   
Exploring the Brain (Lippincott Williams & Wilkins, Balti-
more, MD & Philadelphia, PA, ed. Third, 2007), pp. 857. 
  S. Beckh, M. Noda, H. Lubbert, S. Numa, 6.   Embo J 8, 3611 
(1989). 
  G. S. Bell, J. W. Sander, 7.   Seizure 10, 306 (2001). 
  T. Berg et al., 8.   Epilepsia 44, 1425 (2003). 
  W. T. Blume et al., 9.   Epilepsia 42, 1212 (2001). 
T. Boiko et al., 10.   Neuron 30, 91 (2001). 
Bordey, H. Sontheimer, 11.   Glia 30, 27 (2000). 
D. F. Bu et al., 12.   Proc Natl Acad Sci U S A 89, 2115 (1992). 
B. C. Callaghan, K. Anand, D. Hesdorffer, W. A. Hauser, J. 13.   
A. French, Ann Neurol 62, 382 (2007). 
C. G. Castillo, S. Mendoza, W. J. Freed, M. Giordano, 14.   Behav 
Brain Res 171, 109 (2006). 
W. A. Catterall, V. Trainer, D. G. Baden, 15.   Bull Soc Pathol 
Exot 85, 481 (1992). 
E. A. Cavalheiro, 16.   Ital J Neurol Sci 16, 33 (1995). 
E. A. Cavalheiro et al., 17.   Epilepsia 32, 778 (1991).
M. Chattopadhyay, D. Wolfe, M. Mata, S. Huang, J.C. Glo-18.   
rioso, D.J. Fink, Mol Ther 12, 307-313 (2005).
C. Chen et al., 19.   Proc Natl Acad Sci U S A 99, 17072 (2002). 
UMURF       29            Issue 6
Research Article
R. C. Collins, R. G. Tearse, E. W. Lothman, 20.   Brain Res 280, 
25 (1983). 
N. C. de Lanerolle, J. H. Kim, R. J. Robbins, D. D. Spencer, 21.   
Brain Res 495, 387 (1989). 
M. Dragunow, R. Faull, 22.   J Neurosci Methods 29, 261 (1989). 
M. Dragunow, H. A. Robertson, 23.   Nature 329, 441 (1987). 
C. Dube et al., 24.   Mol Brain Res 63, 139 (1998). 
R. K. Ellerkmann et al., 25.   Neuroscience 119, 323 (2003). 
R.M. Empson, U. Heinemann. 26.   J Physiol 484, 707-720 
(1995).
J. Engel J, in From Neuroscience to Neurology, S. G. Wax-27.   
man, Ed. (Elsevier Academic Press, 2005), pp. 513. 
J. Engel J, 28.   N Engl J Med 334, 647 (1996). 
J. Engel J, P. Williamson, H. Wieser, in Epilepsy: a compre-29.   
hensive textbook (Lippincott-Raven, Philadelphia, 1997), pp. 
2417-2426. 
Epilepsia, 30.   Epilepsia 30, 389 (1989). 
S. Feldblum, R. F. Ackermann, A. J. Tobin, 31.   Neuron 5, 361 
(1990). 
P. A. Felts, S. Yokoyama, S. Dib-Hajj, J. A. Black, S. G. 32.   
Waxman, Brain Res Mol Brain Res 45, 71 (1997). 
G. Fenalti et al., 33.   Nat Struct Mol Biol 14, 280 (2007). 
D. J. Fink, N. A. DeLuca, W. F. Goins, J. C. Glorioso, 34.   Annu 
Rev Neurosci 19, 265 (1996). 
R. A. Fisher, 35.   Journal of the Royal Statistical Society 85, 87 
(1922). 
B. Fotia et al.,36.    J Biol Chem 279, 28930 (2004).
R. French, P. Sah, K. J. Buckett, P. W. Gage,37.    J Gen Physiol 
95, 1139 (1990).
A. Friedman, C.J. Behrens, U. Heinemann, 38.   Epilepsia 48, 
(2007).
J. M. Fritschy, J. Paysan, A. Enna, H. Mohler, 39.   J Neurosci 14, 
5302 (1994).
L. Goldin, 40.   Annu Rev Physiol 63, 871 (2001). 
D. Gordon et al., 41.   Proc Natl Acad Sci U S A 84, 8682 (1987). 
L. Gram, 42.   Epilepsia 35 Suppl 5, S85 (1994). 
L. Gram, O. M. Larsson, A. Johnsen, A. Schousboe, Br 43.   J 
Clin Pharmacol 27 Suppl 1, 13S (1989). 
S. Harrow et al., 44.   Gene Ther 11, 1648 (2004). 
Heinemann U, Beck H, Dreier JP, Ficker E, Stable J,Shang 45.   
CL, Epilepsy Res Supp 7, 273 (1992). 
S. E. Heron, I. E. Scheffer, S. F. Berkovic, L. M. Dibbens, J. 46.   
C. Mulley, Neurotherapeutics 4, 295 (2007). 
D. G. Herrera, H. A. Robertson, 47.   Prog Neurobiol 50, 83 
(1996). 
J. C. Hirsch et al., 48.   Nat Neurosci 2, 499 (1999). 
G. Huberfeld et al., 49.   J Neurosci 27, 9866 (2007). 
H. Jasper, B. Pertuisset, H. Flanigin, 50.   AMA Arch Neurol Psy-
chiatry 65, 272 (1951). 
J. G. Jefferys, 51.   Physiol Rev 75, 689 (1995). 
S. A. Kalwy, M. T. Akbar, R. S. Coffin, J. de Belleroche, D. 52.   
S. Latchman, Brain Res Mol Brain Res 111, 91 (2003). 
Kanter-Schlifke, B. Georgievska, D. Kirik, M. Kokaia, 53.   Mol 
Ther 15, 1106 (2007). 
M. G. Kaplitt et al., 54.   Lancet 369, 2097 (2007).
Kearney et al., 55.   Neuroscience 102, 307 (2001). 
D. Y. Kim et al., 56.   Nat Cell Biol 9, 755 (2007). 
M. Kobayashi, P. S. Buckmaster, 57.   J Neurosci 23, 2440 
(2003). 
P. Kwan, M. J. Brodie, 58.   N Engl J Med 342, 314 (2000). 
H. C. Lai, L. Y. Jan, 59.   Nat Rev Neurosci 7, 548 (2006). 
N. Laprade, J. J. Soghomonian, 60.   Brain Res Mol Brain Res 34, 
65 (1995). 
H. Lee, C. X. Chen, Y. J. Liu, E. Aizenman, K. Kandler, 61.   Eur 
J Neurosci 21, 2593 (2005). 
P. Leite, N. Garcia-Cairasco, E. A. Cavalheiro, 62.   Epilepsy Res 
50, 93 (2002). 
J. Liu et al., 63.   Brain Res 1073-1074, 297 (2006). 
J. Liu et al., 64.   Mol Ther 10, 57 (2004). 
C. Lossin, D. W. Wang, T. H. Rhodes, C. G. Vanoye, G. A. 65.   
L. Jr, Neuron 34, 877 (2002). 
Lothman EW, Stringer JL,Bertram EH, 66.   Epilepsy Res Supp 7, 
301 (1992). 
C. C. Lu, D. W. Hilgemann, 67.   J Gen Physiol 114, 445 (1999). 
W. Macewen, 68.   Glasgow Med J, 210 (1879). 
R. M. MacKie, B. Stewart, S. M. Brown, 69.   Lancet 357, 525 
(2001). 
D. Malo et al., 70.   Genomics 10, 666 (1991). 
J. H. Margerison, J. A. Corsellis, 71.   Brain 89, 499 (1966). 
J. M. Markert et al., 72.   Gene Ther 7, 867 (2000). 
D. L. Martin, K. Rimvall, 73.   J Neurochem 60, 395 (1993). 
G. W. Mathern, T. L. Babb, J. K. Pretorius, J. P. Leite, 74.   J Neu-
rosci 15, 3990 (1995). 
D. A. McCormick, D. Contreras, 75.   Annu Rev Physiol 63, 815 
(2001). 
T. J. McCown, 76.   Mol Ther 14, 63 (2006). 
B. S. Meldrum, M. A. Rogawski, 77.   Neurotherapeutics 4, 18 
(2007). 
D. M. Mellerick, N. W. Fraser, 78.   Virology 158, 265 (1987). 
E. Mello et al., 79.   Epilepsia 34, 985 (1993). 
D. J. Messner, W. A. Catterall, 80.   J Biol Chem 260, 10597 
(1985).
R. Miles, K. Toth, A. I. Gulyas, N. Hajos, T. F. Freund, 81.   Neu-
ron 16, 815 (1996). 
C. J. Murray, A. D. Lopez, D. T. Jamison, 82.   Bull World Health 
Organ 72, 495 (1994).
Nakao et al., 83.   Ann Oncol 15, 988 (2004). 
E. J. Nestler, S. E. Hyman, R. C. Malenka, Molecular 84.   
Neuropharmacology: A Foundation for Clinical Neuroscience 
(McGraw-Hill, , 2001), pp. 539. 
K. C. New, K. Gale, R. L. Martuza, S. D. Rabkin, 85.   Brain Res 
Mol Brain Res 61, 121 (1998). 
Y. Oh, J. A. Black, S. G. Waxman, 86.   Brain Res Mol Brain Res 
23, 57 (1994). 
J. W. Olney, T. de Gubareff, J. Labruyere, 87.   Nature 301, 520 
(1983). 
T. S. Otis, Y. De Koninck, I. Mody, 88.   Proc Natl Acad Sci U S 
A 91, 7698 (1994). 
V. Papanastassiou et al., 89.   Gene Ther 9, 398 (2002). 
H. R. Pathak et al., 90.   J Neurosci 27, 14012 (2007).
V. Puskovic, D. Wolfe, J. Goss, S. Huang, M. Mata, J.C. 91.   
Glorioso, D.J. Fink, Mol Ther, 10, 67-75 (2004).
R. J. Racine, 92.   Electroencephalogr Clin Neurophysiol 32, 281 
(1972). 
UMURF       30            Issue 6
Research Article
R. Raedt, A. Van Dycke, K. Vonck, P. Boon, 93.   Seizure 16, 565 
(2007). 
R. Rampling et al., 94.   Gene Ther 7, 859 (2000). 
G. B. Richerson, Y. Wu, 95.   J Neurophysiol 90, 1363 (2003). 
C. Richichi et al., 96.   J Neurosci 24, 3051 (2004). 
C. Rivera et al., 97.   Nature 397, 251 (1999). 
J. J. Robert et al., 98.   Gene Ther 4, 1237 (1997). 
J. S. Rougier et al., 99.   Am J Physiol Cell Physiol 288, C692 
(2005). 
M. Rush et al., 100.   Proc Natl Acad Sci U S A 103, 8245 (2006). 
J. W. Sander, 101.   Curr Opin Neurol 16, 165 (2003). 
J. W. Schmidt, W. A. Catterall, 102.   Cell 46, 437 (1986). 
F. Semah et al., 103.   Neurology 51, 1256 (1998). 
T. Shih, D. Lowenstein, 104.   Ann Neurol 62, 311 (2007).
Sillanpaa, D. Schmidt, 105.   Brain 129, 617 (2006). 
M. R. Smith, R. D. Smith, N. W. Plummer, M. H. Meisler, 106.   
A. L. Goldin, J Neurosci 18, 6093 (1998). 
R. D. Smith, A. L. Goldin, 107.   J Neurosci 18, 811 (1998). 
H. Sontheimer, B. R. Ransom, A. H. Cornell-Bell, J. A. 108.   
Black, S. G. Waxman, J Neurophysiol 65, 3 (1991). 
G. Sperk et al., 109.   Hippocampus 13, 806 (2003). 
J. Srinivasan, M. Schachner, W. A. Catterall, 110.   Proc Natl 
Acad Sci U S A 95, 15753 (1998). 
D. J. Stone, J. Walsh, F. M. Benes, 111.   Brain Res Mol Brain 
Res 71, 201 (1999)
C. Sun, Z. Mtchedlishvili, E. H. Bertram, A. Erisir, J. Ka-112.   
pur, J Comp Neurol 500, 876 (2007). 
C. E. Szoeke et al., 113.   Lancet Neurol 5, 189 (2006). 
L. Turski, C. Ikonomidou, W. A. Turski, Z. A. Bortolotto, 114.   
E. A. Cavalheiro, Synapse 3, 154 (1989). 
W. A. Turski, S. J. Czuczwar, Z. Kleinrok, L. Turski, 115.   Expe-
rientia 39, 1408 (1983). 
M. Vreugdenhil, G. C. Faas, W. J. Wadman, 116.   Neuroscience 
86, 99 (1998). 
S. G. Waxman, 117.   Nat Neurosci 10, 405 (2007). 
S. G. Waxman, 118.   Philos Trans R Soc Lond B Biol Sci 355, 
199 (2000). 
R. E. Westenbroek, D. K. Merrick, W. A. Catterall, 119.   Neuron 
3, 695 (1989). 
R. E. Westenbroek, J. L. Noebels, W. A. Catterall, 120.   J Neuro-
sci 12, 2259 (1992). 
W. R. Whitaker et al., 121.   Neuroscience 106, 275 (2001). 
S. Wiebe, W. T. Blume, J. P. Girvin, M. Eliasziw, 122.   N Engl J 
Med 345, 311 (2001). 
L. Wittner et al., 123.   Neuroscience 108, 587 (2001). 
Y. Wu, W. Wang, A. Diez-Sampedro, G. B. Richerson, 124.   Neu-
ron 56, 851 (2007).
Y. Wu, W. Wang, G. B. Richerson, 125.   J Neurophysiol 89, 2021 
(2003). 
Y. Wu, W. Wang, G. B. Richerson, 126.   J Neurosci 21, 2630 
(2001). 
J. Yang et al., 127.   Mol Ther 15, 542 (2007).
